Does Rallies show 13F holders for ACXP?

Yes. Rallies tracks hedge fund and 13F ownership data for ACXP, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ACXP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACXP. It does not provide personalized investment advice.

ACXP (Acurx Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Acurx Pharmaceuticals, Inc. Common Stock (ACXP) is a publicly traded Healthcare sector company. As of May 21, 2026, ACXP trades at $1.89 with a market cap of $7.74M and a P/E ratio of -0.35. ACXP moved +0.00% today. Year to date, ACXP is -33.92%; over the trailing twelve months it is -77.18%. Its 52-week range spans $1.33 to $44.00. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces ACXP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ACXP stock?

Hedge funds tracked by Rallies that own ACXP include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Acurx Pharmaceuticals, Inc. Common Stock.

ACXP Key Metrics

Key financial metrics for ACXP
Metric	Value
Price	$1.89
Market Cap	$7.74M
P/E Ratio	-0.35
EPS	$-5.32
Dividend Yield	0.00%
52-Week High	$44.00
52-Week Low	$1.33
Volume	67
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-7.97M
Gross Margin	0.00%

Top Hedge Funds Holding ACXP

Citadel Advisors holds 4.00K shares of ACXP, changed -58.76% as of Dec 31, 2024.

Latest ACXP News

Acurx’s DNA pol IIIC Inhibitors Achieve MRSA Reduction and Preserve Gut Diversity — May 4, 2026
Acurx Pharmaceuticals Raises $7.1M Offering with 825,085 Shares and Warrants — Apr 16, 2026
Acurx Wins Korean Patent for DNA Polymerase IIIC Inhibitors, Expanding IP to Six Countries — Mar 30, 2026
Acurx Launches 20-Patient Ibezapolstat Trial Following 96% Phase 2 Cure Rate — Mar 9, 2026
Acurx Wins US Patent 12,534,470 for ACX-375C DNA Polymerase IIIC Inhibitors — Feb 24, 2026

Recent ACXP Insider Trades

Scodari Joseph C bought 24.63K (~$25.00K) on Jan 6, 2025.
Sailer Carl bought 24.63K (~$25.00K) on Jan 6, 2025.
LUCI DAVID P bought 49.26K (~$50.00K) on Jan 6, 2025.

ACXP Analyst Consensus

3 analysts cover ACXP: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.

Common questions about ACXP

Who owns ACXP stock?: Hedge funds tracked by Rallies that own ACXP include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Acurx Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for ACXP?: Yes. Rallies tracks hedge fund and 13F ownership data for ACXP, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ACXP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACXP. It does not provide personalized investment advice.